Cargando…

CD28 engagement inhibits CD73-mediated regulatory activity of CD8(+) T cells

CD28 is required for T cell activation as well as the generation of CD4(+)Foxp3(+) Treg. It is unclear, however, how CD28 costimulation affects the development of CD8(+) T cell suppressive function. Here, by use of Hepa1.6.gp33 in vitro killing assay and B16.gp33 tumor mouse model we demonstrate tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Yo-Ping, Kuo, Lu-Cheng, Lin, Been-Ren, Lin, Hung-Ju, Lin, Chih-Yu, Chen, Yi-Ting, Hsiao, Pei-Wen, Chang, Huan-Tsung, Ko, Patrick Chow-In, Chen, Hsiao-Chin, Chang, Hsiang-Yu, Lu, Jean, Ho, Hong-Nerng, Wu-Hsieh, Betty A., Kung, John T., Chen, Shu-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134507/
https://www.ncbi.nlm.nih.gov/pubmed/34011962
http://dx.doi.org/10.1038/s42003-021-02119-9
Descripción
Sumario:CD28 is required for T cell activation as well as the generation of CD4(+)Foxp3(+) Treg. It is unclear, however, how CD28 costimulation affects the development of CD8(+) T cell suppressive function. Here, by use of Hepa1.6.gp33 in vitro killing assay and B16.gp33 tumor mouse model we demonstrate that CD28 engagement during TCR ligation prevents CD8(+) T cells from becoming suppressive. Interestingly, our results showed that ectonucleotidase CD73 expression on CD8(+) T cells is upregulated in the absence of CD28 costimulation. In both murine and human tumor-bearing hosts, CD73 is upregulated on CD28(−)CD8(+) T cells that infiltrate the solid tumor. UPLC-MS/MS analysis revealed that CD8(+) T cells activation without CD28 costimulation produces elevated levels of adenosine and that CD73 mediates its production. Adenosine receptor antagonists block CD73-mediated suppression. Our data support the notion that CD28 costimulation inhibits CD73 upregulation and thereby prevents CD8(+) T cells from becoming suppressive. This study uncovers a previously unidentified role for CD28 costimulation in CD8(+) T cell activation and suggests that the CD28 costimulatory pathway can be a potential target for cancer immunotherapy.